For its leptomeningeal cancer drug, Plus Therapeutics found the FDA receptive to clinical trial endpoints beyond overall survival. The agency was open to "compartmental based endpoints" measuring efficacy within the targeted CNS area—a significant regulatory shift for non-systemic treatments with no established approval pathway.

Minimal Residual Disease (MRD) negativity is now recognized by regulators as a surrogate endpoint in oncology. Because it is considered 'reasonably likely to predict progression-free survival,' this shift allows drug developers to use MRD data to support accelerated approval pathways, expediting the availability of new therapies.

The LEAP-010 trial excluded patients with vascular involvement due to the drug's bleeding risk. This is a common characteristic in real-world head and neck cancer patients, especially post-radiation. This discrepancy means that even if the drug combination had been successful, its applicability in routine clinical practice would be severely limited.

Zongertinib gained both second-line and frontline FDA approval for HER2-mutant NSCLC based on impressive single-arm study data. This unusual path, forgoing traditional randomized Phase III trials, highlights the FDA's willingness to accelerate access to highly effective drugs in areas of high unmet medical need.

The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.

While initially approved for PIK3CA wild-type patients, Gedatolisib also doubled progression-free survival in patients with PIK3CA mutations compared to the standard of care. This mutation-agnostic benefit simplifies treatment decisions for clinicians, broadens the drug's applicability, and removes the need for mutation-specific testing to determine eligibility.

While depth of response strongly predicts survival for an individual patient, the FDA analysis concludes it cannot yet be used as a surrogate endpoint to replace overall survival in pivotal clinical trials. It serves as a measure of drug activity, similar to response rate, but is not sufficient for drug approval on its own.

The GLORA-IV trial is designed with a dual endpoint, evaluating both patient response rate and overall survival. This structure creates an alternative pathway for regulatory approval based on response rates, which can be assessed faster than survival, strategically de-risking the lengthy and expensive trial process.

Beyond improving progression-free survival, the targeted therapy vorasidenib also provides a significant quality-of-life benefit by improving seizure control. Seizures are a common presenting symptom for low-grade glioma patients, and this added therapeutic effect makes the drug a more holistic treatment option.